Vyteris, Inc. Announces LidoSite Marketing Agreement with LabCorp

Fair Lawn, NJ - Vyteris, Inc. recently announced an agreement granting Laboratory Corporation of America Holdings (LabCorp) , a national leader in clinical laboratory testing, rights to represent and offer Vyteris' LidoSite, the first FDA-approved active transdermal smart patch for relief from pain associated with venipunctures and blood draws among certain patients. The agreement allows LabCorp to make LidoSite available for outpatient use to physician offices nationally.

"We are very pleased to have entered into this agreement with LabCorp, which has the infrastructure and track record of introducing new products to the market to improve patient care," said Timothy J. McIntyre, chief executive officer of Vyteris.

Vyteris' proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows more precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration.

In conjunction with physician guidance, clinical laboratory testing remains one of the most cost-effective ways to help assess, diagnose, treat and monitor patient health. However, 20-25 percent of patients may be pain sensitive or needle phobic, which may interfere with compliance with physician orders for blood testing. LidoSite helps to remove this barrier and can lead to improved patient care and better health outcomes.

Under the terms of the agreement, LabCorp will be the only independent clinical laboratory in the U.S. offering LidoSite for outpatient use to physicians. Further details were not disclosed.

SOURCE: Vyteris, Inc.